TrialThe journal of prevention of Alzheimer's disease2026

Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes.

Richard Perry et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.